PT  - JOURNAL ARTICLE
AU  - Eunkyung Park
TI  - A New Era of Clinical Dopamine Transporter Imaging Using <sup>123</sup>I-FP-CIT
AID  - 10.2967/jnmt.112.111617
DP  - 2012 Dec 01
TA  - Journal of Nuclear Medicine Technology
PG  - 222--228
VI  - 40
IP  - 4
4099  - http://tech.snmjournals.org/content/40/4/222.short
4100  - http://tech.snmjournals.org/content/40/4/222.full
SO  - J. Nucl. Med. Technol.2012 Dec 01; 40
AB  - 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (123I-FP-CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP-CIT is a radioligand for brain dopamine transporter (DAT) imaging that is useful for the differential diagnosis of Parkinson disease (PD) and other diseases that mimic PD. The sensitivity and specificity of 123I-FP-CIT SPECT for PD diagnosis are more than 90% and equivalent to those of other DAT SPECT methods. In the near future, the clinical indications of DAT imaging are expected to be broadened; for example, including treatment response assessment, disease progression monitoring, and early diagnosis of premotor PD in each individual patient.